Benitec Biopharma Inc.

NASDAQ•BNTC

CEO: Dr. Jerel A. Banks M.D., Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2014-06-24

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.

Contact Information

3940 Trust Way, Hayward, CA, 94545, United States

510-780-0819

benitec.com

Market Cap

$322.31M

P/E (TTM)

-12.2

17.4

Dividend Yield

52W High

$17.15

52W Low

$9.85

52W Range

33%

Rank48Top 64.4%

3.3

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 3.3 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q2 2026 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.26+0.00%

4-Quarter Trend

FCF

-$3.79M+0.00%

4-Quarter Trend

2026 Q2 Earnings Highlights

Key Highlights

Cash Position Nearly Doubled Cash and equivalents reached $188.8M as of December 31, 2025, nearly doubling from $97.7M reported on June 30, 2025.

Strong Financing Inflow Net cash provided by financing was $98.2M for six months, driven by $104.5M in common stock issuance proceeds.

Clinical Progress Advancing BB-301 Cohort 2 dosing initiated in Q4 2025; positive 24-month patient follow-up data announced in January 2026.

Operating Cash Burn Improved Net cash used in operations reduced to $7.1M for six months versus $12.3M in the prior comparable period.

Risk Factors

Net Loss Significantly Increased Six-month net loss widened to $20.8M compared to $14.6M in the prior comparable six-month period ending December 31, 2024.

Share-Based Compensation Costs Total share-based compensation expense surged to $12.6M for six months, reflecting a substantial increase over prior year.

Zero Revenue Generation Total revenues remained zero for both three-month and six-month periods ending December 31, 2025, requiring external funding.

Future Financing Required Continued operating losses necessitate obtaining adequate financing to fund development activities beyond the next twelve months.

Outlook

Pivotal Study Design Engagement Plan to engage the FDA mid-2026 to confirm the pivotal study design for the lead candidate BB-301 treatment.

Internal Control Weakness Remedied Material weakness related to share-based compensation calculation review process has been fully remediated by management actions.

Future Capital Needs Assessment Future funding requirements depend on clinical trial costs, regulatory timing, and securing future strategic collaborations.

Manufacturing Alliances Explored Exploring long-term manufacturing alliances to support future commercialization scale and manage cost of goods effectively.

Peer Comparison

Revenue (TTM)

AMRN

$183.87M

-19.6%

CLLS

$75.27M

+158.9%

AUTL

$51.13M

+406.7%

Gross Margin (Latest Quarter)

OCGN

1337.8%

+0.0pp

AMRN

119.2%

+7.3pp

KRRO

100.0%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
RAPT	$959.26M	-14.8	-61.8%	1.6%
OCGN	$754.16M	-10.6	-2626.4%	74.8%
SLDB	$601.08M	-4.4	-73.6%	8.0%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 12, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data